Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:2973
Structure:
Synonyms:
1-Amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetyl hydroxylamino)-6,11,17,22-tetraazaheptaeicosane
138-14-7 (MESYLATE)
1950-39-6 (HCL)
2C10H20N2O3.C5H13N.C3H7NO2
3,9,14,20,25-Pentaazatriacontane-2,10,13,21,24-pentone,
3,9,14,20,25-Pentaazatriacontane-2,10,13,21,24-pentone, 30-amino-3,14,25-trihydroxy-
30-Amino-3,14,25-trihydroxy-3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pentaone
70-51-9
70-51-9 (FREE BASE)
7278-84-4
AB00053447
AIDS-002640
AIDS002640
Ba 29837
Ba 33112
Ba-29837
Ba-33112
BPBio1_000716
BRN 2514118
BSPBio_000650
BSPBio_002131
Butanediamide, N'-(5-((4-((5-(acetylhydroxyamino)pentyl)amino)-1,4-dioxobutyl)hydroxyamino)pentyl)-N-(5-aminopentyl)-N-hydroxy-
Butanediamide, N'-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy-
C06940
CGH-749B
CHEBI:4356
cMAP_000047
D03670
DB00746
Deferoxamide B
Deferoxamin
Deferoxamina
Deferoxamina [INN-Spanish]
Deferoxamine
Deferoxamine (USAN)
Deferoxamine B
Deferoxamine Mesylate
Deferoxamine [USAN:INN]
Deferoxaminum
Deferoxaminum [INN-Latin]
Deferrioxamine
Deferrioxamine B
Desferal
Desferal Mesylate
Desferan
Desferex
Desferin
Desferral
Desferriferrioxamin B
Desferrin
Desferrioxamin
DESFERRIOXAMINE
Desferrioxamine B
DF B
DFO
DFOA
DFOM
DFX
DivK1c_000082
EINECS 200-738-5
Ferrioxamine B, N-benzoyl-
HSDB 3311
ICL-749B
IDI1_000082
KBio1_000082
KBio2_001372
KBio2_002429
KBio2_003940
KBio2_004997
KBio2_006508
KBio2_007565
KBio3_001351
KBio3_002908
KBioGR_000922
KBioGR_002429
KBioSS_001372
KBioSS_002435
LS-124964
N'-(5-((4-((5-(Acetylhydroxamino)pentyl)amino)-1,4-dioxobutyl) hydroxyamino)pentyl)-N-(5-aminopentyl)-N-hydroxybutanediamide
N'-[5-(acetyl-hydroxy-amino)pentyl]-N-[5-[3-(5-aminopentyl-hydroxy-carbamoyl)propanoylamino]pentyl]-N-hydroxy-butane diamide
N'-[5-(acetyl-hydroxyamino)pentyl]-N-[5-[[4-(5-aminopentyl-hydroxyamino)-4-oxobutanoyl]amino]pentyl]-N-hydroxybutanediamide
N'-{5-[acetyl(hydroxy)amino]pentyl}-N-(5-{4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanamido}pentyl)-N-hydroxybutanediamide
N'-{5-[acetyl(hydroxy)amino]pentyl}-N-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxybutanediamide
N-(5-(3-((5-Aminopentyl)hydroxycarbamoyl)propionamido)pentyl)-3-((5-(N-hydroxyacetamido)pentyl)carbamoyl)propionohydroxamic acid
N-(5-{3-((5-Aminopentyl)hydroxycarbamoyl)propionamido}pentyl)-3-{(5-(N-hydroxyacetamido)pentyl)carbamoyl}propionohydroxamic acid
N-Benzoylferrioxamine B
NCGC00178802-01
NCGC00178802-02
nchembio.2007.23-comp8
NCI60_002181
NINDS_000082
NSC-527604
NSC268993 (HCL)
NSC527604
NSC527604 (FREE BASE)
NSC644468 (MESYLATE)
N~1~-(5-(Acetyl(hydroxy)amino)pentyl)-N~4~-(5-((4-((5-aminopentyl)(hydroxy)amino)-4-oxobutanoyl)amino)pentyl)-N~4~-hydroxysuccinamide
Perineurin
Prestwick0_000725
Prestwick1_000725
Prestwick2_000725
Prestwick3_000725
Propionohydroxamic acid, N-(5-(3-((5-aminopentyl)hydroxycarbamoyl)propionamido)pentyl)-3-((5-(N-hydroxyacetamido)pentyl)carbamoyl)-
Propionohydroxamic acid, N-[5-(3-[(5-aminopentyl)hydroxycarbamoyl]propionamido)phentyl]-3-([5-(N-hydroxyacetamido)pentyl]carbamoyl)-
Propionohydroxamic acid, N-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[(5-N-hydroxyacetamido)pentyl]carbamoyl]-
Propionohydroxamic acid, N-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]-
SMP2_000121
SPBio_001109
SPBio_002589
Spectrum2_001155
Spectrum3_000376
Spectrum4_000311
Spectrum5_000827
Spectrum_000892
WLN: Z5NQV/2VM5NQV/ 21
ATC-Codes:
Side-Effects:
Side-EffectFrequency
loss of vision0.0010
pain0.0010
paraesthesia0.0010
pruritis0.0010
retinal degeneration0.0010
visual field defects0.0010
swelling0.0010
tinnitus0.0010
erythema0.0010
urticaria0.0010
vascular disorders0.0010
vomiting0.0010
encephalopathy0.0010
cataracts0.0010
bone pain0.0010
myalgia0.0010
lung infiltration0.0010
blurred vision0.0010
optic neuritis0.0010
night blindness0.0010
nausea0.0010
diarrhea0.0010
corneal opacities0.0010
connective tissue disorders0.0010
asthma0.0010
arthralgia0.0010
angioneurotic oedema0.0010
anaphylactic shock0.0010
abdominal pain0.0010
dizziness0.0010
oedema0.0010
mediastinal disorders0.0010
hypotension0.0010
blood disorder0.0010
deafness neurosensory0.0010
headache0.0010
gastroenteritis0.0010
pyrexia0.0010
rash0.0010
allergic reaction0
infection0
retinopathy0
neuropathy0
ards0
tachycardia0
dyspnea0
leg cramps0
thrombocytopenia0
hypersensitivity0
dysuria0
leukopenia0

Target

show target details
Uniprot ID:CP1A1_HUMAN
Synonyms:
CYPIA1
Cytochrome P450 1A1
P450 form 6
P450-C
P450-P1
EC-Numbers:1.14.14.1
Organism:Homo sapiens
Human
PDB IDs:-

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

10799651
Inhibition of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-stimulated Cyp1a1 promoter activity by hypoxic agents.. J E Kim; Y Y Sheen (2000) Biochemical pharmacology display abstract
Since hypoxia-inducible factor-1alpha (HIF-1alpha) and the arylhydrocarbon receptor (AhR) shared the AhR nuclear translocator (Arnt) for hypoxia- and AhR-mediated signaling, respectively, it was possible to establish the hypothesis that hypoxia could regulate cytochrome P450 1a1 (Cyp1a1) expression. In order to test this hypothesis, we undertook to examine the effect of hypoxia on Cyp1a1 transcription in Hepa-I cells. Mouse Cyp1a1 5'-flanking DNA, 1.6 kb was cloned into pGL3 expression vector in order to construct pmCyp1a1-Luc. Hepa-I cells were transfected with pmCyp1a1-Luc and treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in the presence or absence of various hypoxic agents such as 1-100 microM cobalt chloride, 1-100 microM picolinic acid, and 1-100 microM desferrioxamine. Luciferase activity of the reporter gene was measured from pmCyp1a1-Luc-transfected Hepa-I cell lysate which contains 2 microgram total protein using luciferin as a substrate. Hypoxic agents such as cobalt chloride, picolinic acid, and desferrioxamine showed inhibition of luciferase activity that was induced by 1-nM TCDD treatment in a dose-and time-dependent manner. Concomitant treatment of 150 microM ferrous sulfate with 1-100 microM desferrioxamine or 1-100 microM picolinic acid recovered luciferase activity from that inhibited by hypoxic agents or induced by TCDD. These data demonstrated that iron-chelating and hypoxic agents inhibited dioxin-induced Cyp1a1 transcription in Hepa-I cells. Thus, we might suggest that hypoxia inhibits TCDD-induced Cyp1a1 expression due to the competition between HIF-1alpha and the AhR for the Arnt in Hepa-I cells.